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Background
We compare immune responses in humans and rhesus for
two popular concepts for an AIDS vaccine, DNA priming
and MVA boosting vs MVA priming and boosting.
Methods
Identical doses of HIV and SIV Gag-Pol-Env-expressing
DNA (3 mg) and MVA (1 × 108 TCID50) vaccines were
tested in humans (HVTN 065) (n = 30) and rhesus (Yerkes
M11) (n = 8), respectively. Two protocols were used: DNA
at weeks 0 and 8, followed by MVA at weeks 16 and 24
(DDMM) or MVA at weeks 0, 8 and 24 (MMM). Assays for
T cells (ICS) and anti-Env Ab (ELISA) were conducted at
HVTN (human) or Emory Vaccine Center (macaque) labs
at one or two weeks post immunizations.
Results
Whereas rhesus had 100% response rates for all parame-
ters, all human response rates were <80%. In both species,
DNA priming resulted in both higher and more CD4-
biased T cell responses. Humans had higher CD4 than
CD8 response rates (77% vs. 42%) and macaques, greater
magnitudes of elicited CD4 than CD8 cells (medians of
1.57% vs 0.19%). In both species, DNA-primed CD4
responses had >2.4-fold greater breadth than MVA-
primed CD4 cells. Interestingly, both species, for both reg-
imens, had similar peak magnitudes (medians of ~0.15%
of total CD8 cells) and breadths of responding CD8 T cells
(2 out of 5 tested pools in humans and 5 out of 24 pools
in macaques). In both species, MVA-only immunizations
elicited the highest anti-Env Ab responses. In humans,
MMM elicited more frequent responses (75% vs 27%)
and in both species, >2-times higher titer responses than
DDMM. Macaques were much more permissive (~50-
times) for Ab responses than humans achieving median
titers of ~14 μg per ml for the MMM regimen.
Conclusion
(i) DDMM and MMM immunization elicit distinctive pat-
terns of responses and (ii) immune responses in rhesus
are only partial predictors for those in humans.
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